Search academic texts

Information × Registration Number 0210U003496, 0106U012553 , R & D reports Title To Develop the methods of complex treatment of patients with tumors of locomotor system with taking into account structurally-biological peculiarities of malignancies. popup.stage_title Head Korovin Sergey Igorevich, Доктор медичних наук Registration Date 08-02-2010 Organization Nacional Cancer Institute popup.description2 A report is on the research: "The development of methods of complex treatment of sick people locomotor tumors including structure-biological specialities of tumors" 65 pp. 14, fig., 21 tablets., 5 additions, 48 sources. A research object is patients with malignant formations of bones, soft tissue and melanoma of skin. A research purpose - to promote treatment effectivity of patients with the tumors locomotor apparatus by development of methods of complex treatment with structurally biological features of new formations. Research methods, apparatura - clinical, morphological, immunogistochemical, statistical; ultrasonic vehicle of ATL HDI - 5000, computer tomograph "Somatom 4 Plus", magnetically resonance tomograph "Magnetom", angiograf "Televiks", gammatherapeutic vehicle "Rokus". It is established that the expression of immunohistochemical markers p53, Ki-67 are factors of disease prognosis in patients with soft tissue sarcoma (STS). Shown that the expression of these markers is reduced or completely disappeared in 85.7% of patients under the influence of neoadjuvant therapy, which suggests the possibility of their use for evaluating the effectiveness of the treatment. Integrated treatment with adjuvant therapy of patients with STS in the presence of p53 expression markers and Ki-67 promoted the growth rate 2-year overall survival of 12.8%. In patients with bone sarcoma (BS) proved prognostic significance of expression of immunohistochemical markers of Her2/neu and p53, as well as the level of serological vascular endothelial growth factor (VEGF). The technique of intensified chemotherapy in the treatment of patients with BS definite expression of markers led to an increase in rate 2-year overall survival of 12.0%. Developed endolymphatic therapy using low doses cyclophosphane and ?-2b interferon allowed at 5.5% improve your 2-year overall survival of patients with primary localized melanoma of the skin. Methods of treating patients with metastatic melanoma in regional lymph nodes using recombinant ?-2b interferon in high doses in combination with low doses cyclophosphane led to an increase in the total figure 2-year survival of 12.5%. The technique can be applied in practical oncology and orthopedics to improve the treatment results of patients (lengthening life expectancy of patients) neoplasms of bone, soft tissue and skin. Product Description popup.authors Бойчук Сергій Іванович Волков Ігор Борисович Головко Тетяна Сергіївна Дєдков Анатолій Григорович Кукушкіна Марія Миколаївна Куценко Любов Борисівна Мельник Микола Миколайович Новак Олена Милославівна Палівець Андрій Юрієвич Тарасова Тетяна Олександрівна Чорний Володимир Сергійович popup.nrat_date 2020-04-02 Close